SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer

BACKGROUND: In the last decade, several tyrosine kinase inhibitors (TKIs), which disrupt pathways involved in the proliferation and tumorigenesis of thyroid cancer, have been extensively studied. Two different TKIs, lenvatinib and sorafenib, were recently approved by both the US FDA and European Med...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Soo Young, Kim, Seok-Mo, Chang, Ho-Jin, Kim, Bup-Woo, Lee, Yong Sang, Park, Cheong Soo, Park, Ki Cheong, Chang, Hang-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172752/
https://www.ncbi.nlm.nih.gov/pubmed/30286728
http://dx.doi.org/10.1186/s12885-018-4854-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172752/
https://www.ncbi.nlm.nih.gov/pubmed/30286728
http://dx.doi.org/10.1186/s12885-018-4854-z

Ejemplares similares